Evaluation of outcomes of 8-week therapy with ledipasvir/sofosbuvir or glecaprevir/pibrentasvir in veterans with hepatitis C infection
Open Access
- 13 November 2019
- journal article
- Published by Heighten Science Publications Corporation in Annals of Clinical Gastroenterology and Hepatology
- Vol. 3 (1), 027-030
- https://doi.org/10.29328/journal.acgh.1001011
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1–6 Hepatitis C Virus Infections and Compensated Liver DiseaseClinical Infectious Diseases, 2019
- Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or olderPLOS ONE, 2019
- Treatment efficacy of ledipasvir/sofosbuvir for 8 weeks in non-cirrhotic chronic hepatitis C genotype 4 patientsSaudi Journal of Gastroenterology, 2019
- Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapyHepatology International, 2018
- Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in EgyptGut, 2018
- Eight-Week Outcomes of Ledipasvir/Sofosbuvir in Noncirrhotic Treatment-Naive Patients with Hepatitis C: Analysis of Pharmacy-Based DataJournal of Managed Care & Specialty Pharmacy, 2018
- Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trialJournal of Hepatology, 2017
- Should we screen for cirrhosis?BMJ, 2017
- Global distribution and prevalence of hepatitis C virus genotypesJournal of Hepatology, 2014
- Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without CirrhosisThe New England Journal of Medicine, 2014